Friday, September 8, 2023
News Health
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Insulet Shares Slump on Concerns of New Diabetes Drugs Sales

September 8, 2023
in Health News
Share on FacebookShare on Twitter


(Reuters) – Insulet Corp’s shares hit an over three-year low on Thursday on concerns that strong demand for a new class of diabetes drugs that also aid in weight loss could hit sales of its insulin pumps.

CEO James Hollingshead said at the Wells Fargo Healthcare Conference that GLP-1 drugs, which are used to treat type-2 diabetes and obesity, could delay the onset of insulin dependency in diabetes patients.

“What we might see is GLP-1s impacting the time to progression on the insulin therapy,” said Hollingshead, adding that the company does not expect its long-term market for insulin pumps to be impacted.

GLP-1s are highly effective weight-loss drugs that some analysts predict could become a $100 billion market by 2030. They help regulate blood sugar and also mimic a gut hormone, which reduces appetite and increases the feeling of fullness after eating.

Insulet’s shares were also pressured by data from a 10-patient study published in the New England Journal of Medicine that showed Novo Nordisk’s semaglutide, also called Ozempic or Wegovy, cut the need for mealtime insulin in type 1 diabetes patients.

Data also showed the need for basal insulin, taken between meals, was eliminated in seven patients.

Shares of Massachusetts-based Insulet fell about 12% to $170.87 and were on track to wipe off about $1.6 billion from the company’s market capitalization if losses hold.

Insulet’s executives sought to allay investor concerns over the study, pointing to its small size and arguing that it was common to go through a “honeymoon” period in type 1 diabetes where some patients only need minimal insulin.

“It’s really common (that) insulin needs come down in that first year,” said Insulet’s medical director Trang Ly.

Insulet manufactures and sells insulin delivery devices, which eliminate the need for multiple daily injections for people with insulin-dependent diabetes.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Anil D’Silva and Shinjini Ganguli)



Source link : https://www.medscape.com/s/viewarticle/996190?src=rss

Author :

Publish date : 2023-09-08 13:48:44

Copyright for syndicated content belongs to the linked Source.
Previous Post

Wegovy Received Is ‘Very Small Fraction’ of Waiting List

Next Post

Philips Settles One Category of US Claims Over Respirator Recall

Related Posts

Health News

Philips Settles One Category of US Claims Over Respirator Recall

September 8, 2023
Health News

Wegovy Received Is ‘Very Small Fraction’ of Waiting List

September 8, 2023
Health News

New Covid variant BA.2.86 behind Norfolk care home outbreak

September 8, 2023
Health News

YouTube starts verifying health workers in the UK

September 8, 2023
Health News

NAFLD Raises Risk for Colorectal Adenomatous Polyps

September 8, 2023
Health News

Experts Answer 6 Common Questions

September 7, 2023
Load More

Philips Settles One Category of US Claims Over Respirator Recall

September 8, 2023

Insulet Shares Slump on Concerns of New Diabetes Drugs Sales

September 8, 2023

Wegovy Received Is ‘Very Small Fraction’ of Waiting List

September 8, 2023

New Covid variant BA.2.86 behind Norfolk care home outbreak

September 8, 2023

YouTube starts verifying health workers in the UK

September 8, 2023

NAFLD Raises Risk for Colorectal Adenomatous Polyps

September 8, 2023

Experts Answer 6 Common Questions

September 7, 2023

New Moderna Vaccine to Work Against Recent COVID Variant

September 7, 2023
Load More

Categories

Tags

curcumin (2) diet (2) Keto (2)

Archives

September 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
« Aug    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Anti-Aging
  • Hair Products
  • Nutrition
    • Digestive Health
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version

Insulet Shares Slump on Concerns of New Diabetes Drugs Sales- https://france-restos.com   https://casques-audio.com   https://deguisementdiscount.com   https://www.village-global.com   https://www.pushkar-india.com/   https://materiel-camping.info   https://www.politique-france.com   https://www.atelier-aquariophilie.com   -/- Demystifying Breast Illness Markers | RadioGraphics – RSNA Publications On-line   Les Meilleurs Vêtements « Shorty Femme » pour un Confort Absolu   Des nouvelles de la Nintendo Switch 2, le vélo révolutionnaire de Decathlon est là et un outil pour neutraliser les iPhone – Tech’spresso   -*- L’Arbre Vert Liquide de Rinçage Lave Vaisselle 750 ml Lot de 4   Soldes été 2023 : profitez des meilleures promos tech sur les plus grandes marques   */* Grooves basse & batterie (1 Livre + 1 CD)   Demystifying Breast Illness Markers | RadioGraphics – RSNA Publications On-line   Motorsport news | IndyCar legend Will Power nearly quit for fear of sick wife’s death – WWOS   * Fogo De Chão to open second New Jersey restaurant – Verdict Foodservice   Mayor bids to block pension of rapist ex-Met Police officer   Insulet Shares Slump on Concerns of New Diabetes Drugs Sales *Insulet Shares Slump on Concerns of New Diabetes Drugs Sales

NEWSHEALTH : Insulet Shares Slump on Concerns of New Diabetes Drugs Sales